Alfuzosin Hydrochloride

證據等級: L5

預測適應症: 0 個

Alfuzosin Hydrochloride: Repurposing Evaluation — Insufficient Data to Complete Assessment

One-Sentence Summary

Alfuzosin hydrochloride is a selective alpha-1 adrenergic receptor antagonist widely used internationally for benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS). The current Evidence Pack contains no TxGNN predicted indications for this drug, and the drug has no registered products in Singapore, meaning a full repurposing evaluation cannot be completed at this stage. This report documents existing data gaps and outlines the actions required before proceeding.

Quick Overview

Item	Content
Original Indication	Not available (no Singapore registrations on record)
Predicted New Indication	None — TxGNN returned no predictions in this Evidence Pack
TxGNN Prediction Score	N/A
Evidence Level	N/A
Singapore Market Status	Not marketed
Number of Registrations	0
Recommended Decision	Hold

Safety Considerations

Please refer to the package insert for safety information.

No safety data (warnings, contraindications, or drug interactions) is available in this Evidence Pack. All safety fields are marked as data gaps, and the DDI query returned zero results.

Conclusion and Next Steps

Decision: Hold

Rationale: This Evidence Pack is critically incomplete — TxGNN returned no predicted indications, no Singapore regulatory registrations exist, and key inputs (MOA, safety warnings, contraindications) are all absent. There is no repurposing signal to evaluate at this time.

To proceed, the following is needed:

TxGNN predictions: Re-run the repurposing pipeline with the correct DrugBank ID for Alfuzosin Hydrochloride to generate candidate indications and confidence scores
DrugBank ID resolution: The drugbank_id field is null — retrieve the correct ID (likely DB00346) and re-query to populate MOA, categories, and toxicity data
Safety data: Download and parse the prescribing information PDF to extract key warnings, contraindications, and drug interaction profiles
Regulatory verification: Confirm whether Alfuzosin Hydrochloride has any pending or historical registrations in Singapore through the HSA product registry
Original indication documentation: Record the approved indication (BPH / LUTS) as baseline context for any future mechanistic cross-indication analysis
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.